BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YL, Chang YH, Li CJ, Huang YH, Tsai MC, Chu PY, Lin HY. New Insights into the Role of miR-29a in Hepatocellular Carcinoma: Implications in Mechanisms and Theragnostics. J Pers Med 2021;11:219. [PMID: 33803804 DOI: 10.3390/jpm11030219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Mo W, Cao S. MiR-29a-3p: a potential biomarker and therapeutic target in colorectal cancer. Clin Transl Oncol 2022. [DOI: 10.1007/s12094-022-02978-6] [Reference Citation Analysis]
2 Nguyen TTP, Suman KH, Nguyen TB, Nguyen HT, Do DN. The Role of miR-29s in Human Cancers—An Update. Biomedicines 2022;10:2121. [DOI: 10.3390/biomedicines10092121] [Reference Citation Analysis]
3 Hatmal MM, Al-hatamleh MAI, Olaimat AN, Alshaer W, Hasan H, Albakri KA, Alkhafaji E, Issa NN, Al-holy MA, Abderrahman SM, Abdallah AM, Mohamud R. Immunomodulatory Properties of Human Breast Milk: MicroRNA Contents and Potential Epigenetic Effects. Biomedicines 2022;10:1219. [DOI: 10.3390/biomedicines10061219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shehab-Eldeen S, Metwaly MF, Saber SM, El-Kousy SM, Badr EA, Essa A. MicroRNA-29a and MicroRNA-124 as novel biomarkers for hepatocellular Carcinoma. Dig Liver Dis 2022:S1590-8658(22)00259-6. [PMID: 35525722 DOI: 10.1016/j.dld.2022.04.015] [Reference Citation Analysis]
5 Bell AW. Personalized Medicine for Liver Disease: From Molecular Mechanisms to Potential Targeted Therapies. JPM 2022;12:663. [DOI: 10.3390/jpm12050663] [Reference Citation Analysis]
6 Huang YH, Lian WS, Wang FS, Wang PW, Lin HY, Tsai MC, Yang YL. MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of HIF-1α and ANGPT2. Int J Mol Sci 2022;23:1636. [PMID: 35163556 DOI: 10.3390/ijms23031636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mirzaei S, Saebfar H, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Entezari M, Hushmandi K, Samarghandian S, Aref AR, Ashrafizadeh M, Khan H. MicroRNAs regulating SOX2 in cancer progression and therapy response. Expert Rev Mol Med 2021;23:e13. [PMID: 34583803 DOI: 10.1017/erm.2021.15] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
8 Yang YL, Tsai MC, Chang YH, Wang CC, Chu PY, Lin HY, Huang YH. MIR29A Impedes Metastatic Behaviors in Hepatocellular Carcinoma via Targeting LOX, LOXL2, and VEGFA. Int J Mol Sci 2021;22:6001. [PMID: 34206143 DOI: 10.3390/ijms22116001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]